VYNE Therapeutics (VYNE) Research & Development (2017 - 2026)
VYNE Therapeutics (VYNE) posted Research & Development of $817000.0 for Q1 2026, down 83.26% on a QoQ basis from $4.9 million in Q2 2025, and down 86.66% year-over-year from $6.1 million in Q1 2025.
VYNE Therapeutics (VYNE) Research & Development (2017 - 2026) Analysis & Trends
VYNE Therapeutics' Research & Development history runs 10 years deep, the most recent figure standing at $817000.0 for Q1 2026.
- Quarterly Research & Development fell 86.66% year-over-year to $817000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 35.54% YoY) and the FY2025 annual result came in at $19.2 million, down 37.84% from the prior year.
- Research & Development was $817000.0 for Q1 2026 at VYNE Therapeutics, down from $4.9 million in the prior quarter.
- Across five years, Research & Development topped out at $10.2 million in Q3 2024 and bottomed at $817000.0 in Q1 2026.
- A 5-year average of $5.2 million and a median of $4.5 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development surged 220.34% — and 2026, when it sank 86.66%.
- VYNE Therapeutics' Research & Development stood at $4.3 million in 2022, then decreased by 29.35% to $3.0 million in 2023, then jumped by 220.34% to $9.7 million in 2024, then slumped by 49.6% to $4.9 million in 2025, then tumbled by 83.26% to $817000.0 in 2026.
- Business Quant data shows VYNE's Research & Development at $817000.0 in Q1 2026, $4.9 million in Q2 2025, and $6.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 343.97 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | 817,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 817,000.00 |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 6.12 Mn |
| Dec 31, 2024 | 9.68 Mn |
| Sep 30, 2024 | 10.25 Mn |
| Jun 30, 2024 | 7.31 Mn |
| Mar 31, 2024 | 3.71 Mn |
| Dec 31, 2023 | 3.02 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 7.23 Mn |
| Mar 31, 2023 | 2.73 Mn |
| Dec 31, 2022 | 4.28 Mn |
| Sep 30, 2022 | 5.55 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 4.45 Mn |
| Dec 31, 2021 | 4.32 Mn |
| Sep 30, 2021 | 5.92 Mn |
| Jun 30, 2021 | 5.05 Mn |
| Mar 31, 2021 | 4.26 Mn |
| Dec 31, 2020 | 7.84 Mn |